In brief

  • A vaccine maker, not an AI stock, leads the S&P 500 in 2026

  • Success in a cancer vaccine trial and a Nasdaq-100 listing fueled the rally.

  • The full trial results will be released on October 24. The figures are not yet available.

Read the original story, “Covid vaccine stock in S&P 500 rises 600% this year,” by Lockridge Okoth on fi.beincrypto.com